scholarly journals A metformin-monoterápia és a szitagliptin/metformin fix kombináció egyéves perzisztenciája

2016 ◽  
Vol 157 (16) ◽  
pp. 618-622
Author(s):  
Gábor Simonyi ◽  
Tamás Ferenci
Keyword(s):  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Metformin Monotherapy ◽  
Dose Combination ◽  
One Year ◽  
The One ◽  
Type 2 Diabetic

Introduction: In treatment of type 2 diabetes mellitus it is important to reach glycaemic targets. The elements of this are the adequate diet and the patient’s adherence to medication. Aim: The aim of the authors was to investigate the one year persistence of the metformin monotherapy and sitagliptin/metformin fixed dose combination in type 2 diabetic patients. Method: National Health Insurance Found prescriptions database of Hungary on pharmacy-claims between October 1, 2012 and September 30, 2013 was analyzed. The authors identified patients who filled prescriptions for metformin monotherapy and fixed dose combinations of sitagliptin/metformin prescribed for the first time. Patients have not received similar drugs one year previous to study. To model the persistence, the apparatus of survival analysis was used, where “survival” was the time to abandon the medication. As it was available to month precision, discrete time survival analysis was applied: a generalized linear model was estimated with complementary log-log link function with the kind of drug being the only explanatory variable. Results: During the trial period, metformin monotherapy or sitagliptin/metformin fixed dose combination was started in 63,386 and 10,039 patients, respectively. One year persistence rate in patients with metformin monotherapy was 30%, and 58% in patients with sitagliptin/metformin fixed dose combination. Considering only the 360-day study period, the mean duration of persistence was 173.4 days in patients on metformin monotherapy and 261.9 days on sitagliptin/metformin fixed dose combination. The hazard of discontinuation was more than twofold higher during treatment with metformin monotherapy compared with the use of the sitagliptin/metformin fixed dose combination (hazard ratio = 2.267, p<0.001). Conclusions: There is a significant difference between the one year persistence of metformin monotherapy and sitagliptin/metformin fixed dose combination in type 2 diabetic patients. The result demonstrated sitagliptin/metformin fixed dose combination has a favourable patients’ adherence as compared to metformin monotherapy. Orv. Hetil., 2016, 157(16), 618–622.

scholarly journals PDB21 EVALUATION OF THE ONE-YEAR EFFICIENCY OF THE EDUC@DOM TELEMONITORING AND TELE-EDUCATION PROGRAM FOR TYPE 2 DIABETIC PATIENTS

2020 ◽  
Vol 23 ◽  
pp. S111
Author(s):  
M. Mounié ◽  
N. Costa ◽  
J. Martini ◽  
C. Latorre ◽  
J.C. Buisson ◽  
...  
Keyword(s):  
Education Program ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
One Year ◽  
The One ◽  
Type 2 Diabetic

Clinical Medicine: Endocrinology and Diabetes: Gender-associated Differences in Weight Gain, Insulin Requirement and Metabolic control in Newly Insulin-treated Type 2 Diabetic Patients with Secondary Sulfonylurea Failure–-a One-year Observation

2009 ◽  
Vol 2 ◽  
pp. CMED.S3039
Author(s):  
Georg Biesenbach ◽  
Gert Bodlaj ◽  
Herwig Pieringer
Keyword(s):  
Insulin Therapy ◽  
Metabolic Control ◽  
Vascular Diseases ◽  
Insulin Requirement ◽  
First Year ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
One Year ◽  
Type 2 Diabetic

Objective The aim of the present study was to determine differences between male and female type 2 diabetic patients concerning body weight, metabolic control, insulin requirement and prevalence of vascular diseases during the first year insulin therapy. Patients and Methods We investigated 102 newly insulin-treated type 2 diabetic patients (60 female) with secondary sulfonylurea failure. Observation period was the first year insulin therapy. We compared BMI, HbA1c, lipids and insulin requirement at the begin and after one year, C-peptide and prevalence of vascular diseases at the start of insulin therapy. Results At the start of insulin substitution, omen had a higher BMI (27 + 3 versus 25 + 3; p < 0.05). Women also required a higher insulin dose than did men (28 + 6 versus 24 + 6 IU/day) Mean HbA1c and cholesterol levels were similar in both groups whereas triglycerides were higher in women (244 + 88 versus 203 + 76 mg/dl; p < 0.05). Both groups achieved a similar gain in body weight after one year (+2.5% versus +2.6%; NS). HbA1c decreased from 9.2 + 1.1 to 7.4% + 0.9% (–19%) in women and from 9.4 + 1.1 to 7.5% + 1.0% (–20%) in men. The prevalence of vascular diseases was not significantly different in both groups. Conclusions At the start of insulin therapy female type 2 diabetic patients showed a significant higher BMI and a higher insulin requirement than male patients. The metabolic control was similar in men and women, only the triglycerides were higher in the female patients. Weight gain and increase of needed insulin as well as prevalence of macroangiopathy were the same in both groups.

scholarly journals A ramipril versus ramipril/amlodipin fix kombináció egyéves perzisztenciája hypertoniás betegekben

2017 ◽  
Vol 158 (42) ◽  
pp. 1669-1673 ◽  
Author(s):  
Gábor Simonyi ◽  
Tamás Ferenci
Keyword(s):  
Blood Pressure ◽  
Survival Analysis ◽  
Combination Therapy ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Hypertensive Patients ◽  
Persistence Rate ◽  
Dose Combination ◽  
One Year ◽  
The One

Abstract: Introduction: In the treatment of hypertension avoiding adverse cardiovascular complications to achieve target blood pressure is essential. The appropriate drug selection, and if necessary to change to combination therapy, patients adherence is important which may help fixed dose combination. Aim: The aim of the authors was to investigate the one year adherence of the ramipril and ramipril/amlodipine fixed dose combination in hypertensive patients. Method: Prescriptions database of the National Health Insurance Fund in Hungary on pharmacy-claims was analysed between October 1, 2012 and September 30, 2013. The authors identified patients who filled prescriptions for ramipril monotherapy and fixed dose combinations of ramipril/amlodipine prescribed for the first time in hypertensive patients who have not received similar drugs in the previous year. To model the adherence, the apparatus of survival analysis was used, where “survival” was the time to abandon the medication. As it was available to month precision, discrete time survival analysis was applied: a generalized linear model was estimated with complementary log-log link function with the kind of drug being the only explanatory variable. Results: 92,546 patients met the inclusion criteria. During the trial period, ramipril therapy or ramipril/amlodipine fixed dose combination was started in 82,251 and 10,295 patients, respectively. One year persistence rate in patients with ramipril was 30% and 54% in patients with ramipril/amlodipine fixed dose combination therapy. Considering only the 360-day study period, the mean duration of persistence was 189.9 days in patients on ramipril and 270.6 days on ramipril/amlodipine fixed dose combination therapy. The hazard of discontinuation was more than twofold higher during treatment with ramipril compared with the use of the ramipril/amlodipine fixed dose combination therapy (HR = 2.11 [95% CI: 2.05–2.17], p<0,001). Conclusions: There is a significant difference between the one year persistence of ramipril and ramipril/amlodipine fixed dose combination therapy in hypertension. The result demonstrated that ramipril/amlodipine fixed dose combination therapy has a better one year persistence rate. When the next step is necessary to achieve target blood pressure, ramipril/amlodipine fixed dose combination therapy is preferable. Orv Hetil. 2017; 158(42): 1668–1673.

scholarly journals A perindopril/amlodipin szabad és fix kombinációk egyéves terápiahűsége

2017 ◽  
Vol 158 (36) ◽  
pp. 1421-1425
Author(s):  
Gábor Simonyi ◽  
Tamás Ferenci ◽  
Mihály Medvegy ◽  
Roland Gasparics ◽  
Ervin Finta
Keyword(s):  
Survival Analysis ◽  
Antihypertensive Therapy ◽  
Patient Adherence ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Cardiovascular Risk Reduction ◽  
Pharmacy Claims ◽  
Dose Combination ◽  
One Year ◽  
The One

Abstract: Introduction: In management of hypertension patient adherence is one of the most important factors. In hypertension the cardiovascular risk reduction can be reached only by prolonged and effective pharmacotherapy. Aim: To evaluate the persistence of one-year treatment of free and fixed-dose combination of perindopril/amlodipine in hypertension. Method: Information from the National Health Insurance of Hungary prescriptions database on pharmacy claims between October 1, 2012 and September 30, 2013 was analysed. Authors identified patients who filled prescriptions for free and fixed-dose combination of perindopril/amlodipine, prescribed for the first time for hypertension. Patients have not received antihypertensive therapy with similar active substances during the one year before. Apparatus of survival analysis was used, where “survival” was the time to abandon the medication. As it was available to month precision, discrete time survival analysis was applied. Results: 109,248 patients met the inclusion criteria. Combination antihypertensive therapy with perindopril/amlodipine was started with a free or a fixed-dose combination of these agents in 19,365 and 89,883 patients, respectively. One year persistence rate in patients taking perindopril/amlodipine as a free combination was 27.15%, whereas it was 46.89% in those on the fixed-dose combination. Mean duration of persistence was 177.6 days in patients on the perindopril/amlodipine free, whereas 245.7 days on fixed-dose combination. Actual rate of discontinuation was approximately twice higher with the treatment of free, compared with the use of the fixed-dose combination (hazard ratio =1.94 [95% CI: 1.91–1.98], p<0.001). Orv Hetil. 2017; 158(36): 1421–1425.

scholarly journals Treatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Grigorios Rombopoulos ◽  
Magdalini Hatzikou ◽  
Athanasios Athanasiadis ◽  
Moyses Elisaf
Keyword(s):  
Diabetes Mellitus ◽  
Treatment Compliance ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Combination Group ◽  
Metformin Monotherapy ◽  
Group A ◽  
Dose Combination ◽  
Group B

Objective. To evaluate the differences in treatment compliance with vildagliptin/metformin fixed-dose versus free-dose combination therapy in patients with type 2 diabetes mellitus (T2DM) in Greece.Design. Adult patients with T2DM, inadequately controlled with metformin monotherapy, (850 mg bid), participated in this 24-week, multicenter, observational study. Patients were enrolled in two cohorts: vildagliptin/metformin fixed-dose combination (group A) and vildagliptin metformin free-dose combination (group B).Results. 659 patients were enrolled, 360 were male, with mean BMI 30.1, mean T2DM duration 59.6 months, and mean HbA1c at baseline 8%; 366 patients were assigned to group A and 293 to group B; data for 3 patients was missing. In group A, 98.9% of patients were compliant with their treatment compared to 84.6% of group B. The odds ratio for compliance in group A versus B was (OR) 18.9 (95% CI: 6.2, 57.7;P<0.001). In group A mean HbA1c decreased from 8.1% at baseline to 6.9% (P<0.001) at the study end and from 7.9% to 6.8% (P<0.001) in group B.Conclusions. Patients in group A were more compliant than patients in group B. These results are in accordance with international literature suggesting that fixed-dose combination therapies lead to increased compliance to treatment.

Sign in / Sign up

Export Citation Format

Share Document